<DOC>
	<DOCNO>NCT00976300</DOCNO>
	<brief_summary>Intravenous cyclophosphamide consider standard care treatment proliferative lupus nephritis . However , use limit potentially severe toxic effect . Cyclosporine A suggested efficient safe treatment alternative cyclophosphamide . In randomized , multicenter , open-label , controlled trial investigator seek compare efficacy oral cyclosporine A intravenous pulse cyclophosphamide induce durable remission patient lupus nephritis III-IV .</brief_summary>
	<brief_title>Cyclosporine A Intravenous Cyclophosphamide Lupus Nephritis : The Cyclofa-Lune Study</brief_title>
	<detailed_description>Lupus nephritis occur 30-40 % adult systemic lupus erythematosus associate increased morbidity mortality . Focal diffuse proliferative form lupus nephritis know progress chronic renal failure unless treat immunosuppressive drug . Cyclophosphamide glucocorticoid consider standard care patient proliferative lupus nephritis . However , cyclophosphamide may cause number toxic effect , bone marrow suppression , premature gonadal failure , hemorrhagic cystitis , opportunistic infection , malignant disease . Hence , effort make find alternative therapeutic approach . Cyclosporine potent immunosuppressive agent selective mode action unique effect T cell mediate response , widely use treat spectrum autoimmune glomerular disease . Several retrospective series one randomize trial provide evidence Cyclosporine A could represent efficient safe therapy proliferative lupus nephritis . In randomized , multicenter , open-label , control trial compare efficacy oral cyclosporine A intravenous pulse cyclophosphamide induce durable remission patient proliferative lupus nephritis .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>diagnosis systemic lupus erythematosus ( meet 4 criterion American College Rheumatology ) renal biopsy document lupus nephritis accord classification World Health Organization ( WHO ) update International Society Nephrology/Renal Pathology Society ( ISN/RPS ) proliferative glomerulonephritis class III ( focal ) IV ( diffuse ) clinical activity define presence least two follow : abnormal proteinuria ( 500mg protein 24hour urine specimen ) abnormal microscopic hematuria , C3 hypocomplementemia ( latter two define accord norm laboratory participate center ) treatment cyclophosphamide cyclosporine A ever treatment immunosuppressive drug ( azathioprine mycophenolate mofetil ) high dose glucocorticoid ( ≥ 80mg prednisone methylprednisolone ) within last 3 month persistent elevation serum creatinine ( ≥140 μmol/l ) pregnancy lactation bone marrow insufficiency cytopenia attributable SLE , 8severe coexisting condition , infection , liver disease , active peptic ulcer etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>SLE</keyword>
	<keyword>lupus nephritis</keyword>
	<keyword>cyclosporine A</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>active proliferative lupus nephritis ( class III IV accord WHO )</keyword>
</DOC>